Progressive External Ophthalmoplegia (PEO)/Optic Atrophy Nuclear Gene Panel
ACO2, AUH, C12orf65, CLPB, DGUOK, DNA2, DNAJC19, DNM1L, EARS2, FH, ISCA2, MFF, MFN2, MGME1, MTFMT, MTO1, MTPAP, NARS2, NDUFAF3, NR2F1, OPA1, OPA3, PDHX, PDSS1, POLG, POLG2, RNASEH1, RRM2B, SLC19A2, SLC19A3, SLC25A4, SLC25A46, SPG7, SUCLA2, TACO1, TIMM8A, TK2, TMEM126A, TSFM, TWNK, TYMP, VARS2, WFS1
- Optic Atrophy
- Progressive External Ophthalmoplegia
- Molecular confirmation of a clinical diagnosis
- Testing of patients suspected of having a mitochondrial disorder
- Prenatal diagnosis for known familial mutation(s) in nuclear genes in at-risk pregnancies
- Next-Gen Sequencing
- Deletion/Duplication Analysis
81404x1, 81405x2, 81406x2, 81407x1, 81479x1
*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
**Reporting times are typical and begin once the sample(s) are received at the GeneDx laboratory, but could be extended in situations outside GeneDx’s reasonable control.
Targeted Variant Testing